[.
]
Action/Kinetics:
Possesses anti-inflammatory, antipyretic, and analgesic properties. Known to inhibit both prostaglandin and leukotriene synthesis, to have antibradykinin activity, and to stabilize lysosomal membranes.
Onset: 15-30 min.
Peak plasma levels: 0.5-2 hr.
Duration: 4-6 hr.
t
1/2: 2-4 hr.
t
1/2, geriatrics: Approximately 5 hr. Is 99% bound to plasma proteins. Food does not alter the bioavailability; however, the rate of absorption is reduced.
Uses:
Rx: Acute or chronic rheumatoid arthritis and osteoarthritis (both capsules and sustained-release capsules). Primary dysmenorrhea. Analgesic for mild to moderate pain.
OTC: Temporary relief of aches and pains associated with the common cold, toothache, headache, muscle aches, backache, menstrual cramps, reduction of fever, and minor pain of arthritis.
Investigational: Juvenile rheumatoid arthritis, sunburn, prophylaxis of migraine, migraine due to menses.
Contraindications:
Use during late pregnancy, in children, and during lactation. Use of the extended-release product for acute pain in any client or for initial therapy in clients who are small, elderly, or who have renal or hepatic impairment.
Special Concerns:
Safety and effectiveness have not been established in children. Geriatric clients may manifest increased and prolonged serum levels due to decreased protein binding and clearance. Use with caution in clients with a history of GI tract disorders, in fluid retention, hypertension, and heart failure.
Additional Side Effects
GI: Peptic ulcer,
GI bleeding dyspepsia, nausea, diarrhea, constipation, abdominal pain, flatulence, anorexia, vomiting, stomatitis.
CNS: Headache.
CV: Peripheral edema, fluid retention.
Additional Drug Interactions:
-
Acetylsalicylic acid /
Plasma ketoprofen levels due to
plasma protein binding
-
Hydrochlorothiazide /
Chloride and potassium excretion
-
Methotrexate / Concomitant use
toxic plasma levels of methotrexate
-
Probenecid /
Plasma clearance of ketoprofen and
plasma protein binding
-
Warfarin / Additive effect to cause bleeding
How Supplied:
Capsule: 25 mg, 50 mg, 75 mg;
Capsule, Extended Release: 100 mg, 150 mg, 200 mg;
Tablet: 12.5 mg
Dosage
?Rx: Extended Release Capsules, Capsules
Rheumatoid arthritis, osteoarthritis.
Adults, initial: 75 mg t.i.d. or 50 mg q.i.d.;
maintenance: 150-300 mg in three to four divided doses daily. Doses above 300 mg/day are not recommended. Alternatively, 200 mg once daily using the sustained-release formulation (Oruvail). Decrease dose by one-half to one-third in clients with impaired renal function or in geriatric clients.
Mild to moderate pain, dysmenorrhea.
Adults: 25-50 mg q 6-8 hr as required, not to exceed 300 mg/day. Reduce dose in smaller or geriatric clients and in those with liver or renal dysfunction. Doses greater than 75 mg do not provide any added therapeutic effect.
?OTC: Tablets
Adults, over 16 years of age: 12.5 mg with a full glass of liquid every 4 to 6 hr. If pain or fever persists after 1 hr follow with an additional 12.5 mg. Experience may determine that an initial dose of 25 mg gives a better effect. Do not exceed a dose of 25 mg in a 4- to 6-hr period or 75 mg in a 24-hr period.
